Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura — HERCULES

Acquired Thrombotic Thrombocytopenic Purpura Clinical Trial

Official title:
A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

Status Completed

Clinical Trial Summary

The study was a Phase III, double-blind, placebo-controlled, randomized study to evaluate the efficacy of caplacizumab in more rapidly restoring normal platelet counts as measure of prevention of further microvascular thrombosis

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Acquired Thrombotic Thrombocytopenic Purpura
Purpura
Purpura, Thrombocytopenic
Purpura, Thrombotic Thrombocytopenic

Clinical Trial Details

NCT number	NCT02553317
Study type	Interventional
Source	Sanofi
Contact
Status	Completed
Phase	Phase 3
Start date	November 2015
Completion date	August 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02878603` - Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)	Phase 3
Recruiting	`NCT05876221` - Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura
Recruiting	`NCT05046717` - Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura
Recruiting	`NCT04985318` - Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP
Not yet recruiting	`NCT04021173` - A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)	Phase 2
Completed	`NCT01151423` - Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)	Phase 2